- NZ testing teams for COVID-19 have been applauded for conducting 5 million tests to date.
- Green Cross delivered a revenue of $310 million for the 6 months ended 30 September 2021, up 10% on pcp.
- TruScreen posted strong growth of 25% in revenue for the half-year ended 30 September 2021.
New Zealand’s COVID-19 testing teams have conducted 5 million tests to date. The teams were applauded by the Associate Minister of Health, Dr Ayesha Verrall, on Friday for their hard work and sustained team effort.
After relying on PCR testing, NZ has been provided with rapid antigen tests from this week onwards.
Let’s have a look at how these 5 NZX healthcare stocks are doing.
Image source: © 2021 Kalkine Media, Data source- Refinitiv
Green Cross Health Limited (NZX:GXH)
Primary healthcare provider, Green Cross, reported a 10% increase in revenue on pcp to $310 million and a 9% rise in NPAT to $9.7 million for the 6 months ended 30 September 2021. GXH reported an increase in activity across all its 3 divisions and $7.2 million of acquisition investment during the six-month period.
GXH declared an interim dividend of 3cps for the period.
GXH ended the day flat at $1.2.
Fisher & Paykel, a designer, manufacturer, and supplier of respiratory care products, reported a 1% drop in total operating revenue and a 2% drop in NPAT to $900 million and $222 million, respectively, for the 6 months ended 30 September 2021.
FPH will pay an interim dividend of 17cps on 15 December 2021. The Company also expects to invest nearly $700 million in land and buildings over the upcoming 5 years.
FPH ended the day 0.95% in red to close at $32.27.
Ebos Group Limited (NZX:EBO)
A marketer and distributor of medical products across the Australasian region, Ebos Group, reported a revenue of over $9 billion for FY21, up 5% on pcp. This increase was majorly propelled by growth in its healthcare and animal care segments.
The Group’s revenue and earnings saw a 10% rise in Q3 ended 30 September on pcp. It announced a final dividend of $46 cps.
EBO ended the day 0.69% in red to close at $35.75.
Pacific Edge Limited (NZX:PEB)
Cancer diagnostics company, Pacific Edge, reported a 66% growth in revenue to $66.7 million for the 6 months ended 30 September 2021 on pcp. The Group’s US sales team increased from 16 to 28 in the period.
The Group is placed well to take advantage of commercial objectives with scaled up operations in the US and a strong balance sheet.
PEB ended the day 0.8% in red to close at $1.24.
TruScreen Group Limited (NZX:TRU)
A manufacturer of cervical screening devices, TruScreen, posted strong growth of 25% in revenue and a 20% reduction in operating loss to $1.26 million for the half-year ended 30 September 2021.
The Group has also persisted with expansion in the world’s most established market, China.
TRU ended the day 1.28% in green to close at $0.079.
The country’s healthcare system must keep innovating to fight pandemics like COVID-19.
(NOTE: Currency is reported in NZ Dollar unless stated otherwise)